What is the clinical evidence from this study?

Study design: Review. Population: Neuroendocrine neoplasms (NENs). Intervention: FAPI PET imaging vs. SSTR PET or [18F]FDG PET.

What question did this study set out to answer?

This review aims to assess the biological basis and clinical implications of FAPI PET in neuroendocrine neoplasms.

July 11, 2026EJNMMI ReportsOpen Access

FAPI: a solution to all, what about NENs?

Q: What does this research mean for the field?

FAP-targeted PET imaging provides complementary diagnostic information for neuroendocrine neoplasms by targeting cancer-associated fibroblasts in the tumor stroma. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

FAPI PET shows potential to complement SSTR and FDG PET in identifying stroma-rich neuroendocrine neoplasms.

Why the study?

What is the biological rationale, current evidence, and potential clinical role of FAPI PET in the imaging and management of neuroendocrine neoplasms?

Population

Patients with neuroendocrine neoplasms (NENs)

Design

Review

Authors

ÖEÖzgül Ekmekçioğlu FCFiliz Celik SHSimon Hughes

Discussion

Member takes

Implication

May complement FDG PET in neuroendocrine neoplasms; leaves open routine use pending prospective validation.

Key Points

This review aims to assess the biological basis and clinical implications of FAPI PET in neuroendocrine neoplasms.
Evaluated current evidence for FAPI PET imaging in the context of neuroendocrine neoplasms.
Discussed the biological rationale for targeting cancer-associated fibroblasts with FAPI PET.
FAPI PET offers improved tumor-to-background contrast in lesions with low [¹⁸F]FDG avidity.
Stromal imaging may yield complementary information not available through conventional imaging techniques.

Structured PICO

What is the biological rationale, current evidence, and potential clinical role of FAPI PET in the imaging and management of neuroendocrine neoplasms?

Population

Patients with neuroendocrine neoplasms (NENs)

Intervention

Fibroblast activation protein (FAP)-targeted PET imaging (FAPI PET)

Outcome

Biological rationale, current evidence, and potential clinical role of FAPI PET in the imaging and management of NENs

FAPI PET imaging may provide complementary information to conventional modalities in the management of neuroendocrine neoplasms by targeting cancer-associated fibroblasts.

Limitations

Current NEN specific evidence is limited and based on case reports, small series, or pan-cancer exploratory studies.
Superiority over [18F]FDG has never been demonstrated in properly designed prospective registration trials.
The specificity and biological underpinnings of FAPI uptake across tumor entities remain incompletely understood.

Cite This Study

Ekmekçioğlu et al. (2026) conducted a review in Neuroendocrine neoplasms (NENs). FAPI PET imaging vs. SSTR PET or [18F]FDG PET was evaluated. FAPI PET imaging shows potential as a complementary diagnostic tool to SSTR and FDG PET in neuroendocrine neoplasms, particularly for identifying stroma-rich high-grade tumors and mesenteric desmoplasia.

synapsesocial.com/papers/6a51dce1c18d7f28ca4ffd0f https://doi.org/10.1186/s41824-026-00321-8

View Full Paper

Ask AI

Bookmark

FAPI: a solution to all, what about NENs?

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

FAPI: a solution to all, what about NENs?

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider